MARLBOROUGH, Mass.--(BUSINESS WIRE)--April 4, 2006--Sepracor Inc. (Nasdaq: SEPR - News) today announced that data from its Phase IIIB/IV, 545-patient study of LUNESTA(TM) brand eszopiclone in patients with insomnia and co-existing major depressive disorder (MDD) have been published.
